Warning letter · FDA Warning Letters, Historical Archive

U4Life LLC dba Mitadone: FDA Warning Letter 542731 (Jan 11, 2018)

Agency action: Jan 11, 2018Record ID: fda_warning_-c94cdf1065c5c8a1
View official source ↗

What happened

Original notice title

U4Life LLC dba Mitadone MARCS-CMS 542731, January 11, 2018

From the archived source record

In addition, the Federal Trade Commission has reviewed your marketing claims for “Mitadone Anti-Opiate Aid Plus Extra Strength” for potential violations of Sections 5 and 12 of the FTC Act, 15 U.S.C §§ 45(a) and 52. A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, “Mitadone Anti-Opiate Aid Plus Extra Strength” fails to bear adequate directions for its intended uses and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)]. The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your product. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and/or injunction. Violations of the FTC Act may result in legal action in the form of a Federal District Court Injunction or an Administrative Order and may require that you pay money back to consumers. With regard to the advertising claims discussed above, please notify Edward Glennon of the FTC via electronic mail at eglennon@ftc.gov , within fifteen working days of receipt of this letter, of the specific actions you have taken to address FTC’s concerns. With regard to the FDA-related violations described in this letter, please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct the violations noted above.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
2b8d2149809d

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Mitadone Anti-Opiate Aid Plus Extra Strength; Detox Center | Withdrawal Aid; Withdrawal Aid | Opiate Withdrawal; MITADONE – OPIATE WITHDRAWAL AID SUPPLEMENT; Elimidrol; Withdrawal Ease; Recovery Ease
Company
U4Life LLC dba Mitadone
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.